JP2012136519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012136519A5 JP2012136519A5 JP2012004674A JP2012004674A JP2012136519A5 JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5 JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- structures
- terminal side
- spacer polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 125000006850 spacer group Chemical group 0.000 claims 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012004674A JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006057475 | 2006-03-03 | ||
| JP2006057475 | 2006-03-03 | ||
| JP2012004674A JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Division JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012136519A JP2012136519A (ja) | 2012-07-19 |
| JP2012136519A5 true JP2012136519A5 (cg-RX-API-DMAC10.html) | 2013-05-30 |
| JP5901299B2 JP5901299B2 (ja) | 2016-04-06 |
Family
ID=38459178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Expired - Fee Related JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
| JP2012004674A Expired - Fee Related JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Expired - Fee Related JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090304715A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2610268A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5598894B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2638804C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2602439T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007100083A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| SI2185589T1 (sl) | 2007-06-01 | 2016-04-29 | University Of Maryland Baltimore | Vezavna sredstva za Fc receptor konstantne regije imunoglobulina |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| WO2010065578A2 (en) * | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
| WO2012002562A1 (en) * | 2010-06-30 | 2012-01-05 | Tokyo University Of Science Educational Foundation Administrative Organization | Modified protein therapeutics |
| WO2012016073A2 (en) | 2010-07-28 | 2012-02-02 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価抗原結合タンパク質 |
| WO2012116926A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| KR20150058236A (ko) | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
| CN104955839A (zh) | 2013-01-28 | 2015-09-30 | 株式会社伊贝克 | 对人偏肺病毒具有特异性的人抗体或其抗原结合性片段 |
| US10519194B2 (en) | 2013-07-12 | 2019-12-31 | Merck Patent Gmbh | Removal of fragments from a sample containing a target protein using activated carbon |
| ES2935274T3 (es) * | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| IL309260B2 (en) | 2015-07-24 | 2025-01-01 | Gliknik Inc | Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding |
| US11466093B2 (en) | 2015-07-27 | 2022-10-11 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| CA3026420A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| BR112019009484A2 (pt) | 2016-12-09 | 2019-07-30 | Gliknik Inc | otimização de fabricação de gl-2045, um stradomer multimerizador |
| BR112019009495A2 (pt) | 2016-12-09 | 2019-08-06 | Gliknik Inc | métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes |
| US20200040084A1 (en) * | 2017-01-06 | 2020-02-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| WO2020014429A2 (en) * | 2018-07-11 | 2020-01-16 | Kurtagic Elma | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 |
| KR20240137083A (ko) | 2022-01-28 | 2024-09-19 | 에베크 인코포레이티드 | 변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
| DE3908834A1 (de) | 1989-03-17 | 1990-09-20 | Hollingsworth Gmbh | Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde |
| CA2437958C (en) * | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| CA2832136C (en) * | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| CA2553883C (en) * | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
-
2007
- 2007-03-02 US US12/281,437 patent/US20090304715A1/en not_active Abandoned
- 2007-03-02 ES ES07737666.3T patent/ES2602439T3/es active Active
- 2007-03-02 EP EP13001539.9A patent/EP2610268A1/en not_active Withdrawn
- 2007-03-02 WO PCT/JP2007/054018 patent/WO2007100083A1/ja not_active Ceased
- 2007-03-02 CA CA2638804A patent/CA2638804C/en not_active Expired - Fee Related
- 2007-03-02 EP EP07737666.3A patent/EP2006305B1/en not_active Not-in-force
- 2007-03-02 JP JP2008502861A patent/JP5598894B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-13 JP JP2012004674A patent/JP5901299B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-12 US US16/538,482 patent/US20190367630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502568B1 (en) | Anti-psgl-1 antibodies and uses thereof | |
| JP2012116856A5 (cg-RX-API-DMAC10.html) | ||
| SG10201909806SA (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| JP2014526898A5 (cg-RX-API-DMAC10.html) | ||
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| JP2012254083A5 (cg-RX-API-DMAC10.html) | ||
| JP2012034692A5 (cg-RX-API-DMAC10.html) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| AR085383A1 (es) | Anticuerpos contra el il33r humano y usos de los mismos | |
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| WO2013095738A3 (en) | Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins | |
| WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20161298T1 (hr) | Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba | |
| WO2015138600A3 (en) | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| HK1257441A1 (zh) | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 | |
| JP2013527761A5 (cg-RX-API-DMAC10.html) | ||
| JP2013241409A5 (cg-RX-API-DMAC10.html) | ||
| MX352338B (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 |